Characterizing informational needs and information seeking behavior of patients with breast cancer

Ludwigson, Abigail; Huynh, Victoria; Vemuru, Sudheer; Romandetti, Karina; Fisher, Christine; Coons, Helen L.; Pettigrew, Jessica; Hampanda, Karen; Kaoutzanis, Christodoulos; Ahrendt, Gretchen; Afghahi, Anosheh; Stewart, Camille; Tevis, Sarah

doi:10.1016/j.amjsurg.2023.09.047

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the Internet is also used as a source of information (also reflected in high agreement scores). A recent study of newly diagnosed breast cancer patients found similar results: in this study, physicians and nurses were the most important sources of information, closely followed by the Internet which was used by 81% of all patients in this study ( 31 ). Numerous other studies also report the use of the Internet as an important source of information ( 26 , 32 ).…”

Section: Discussionsupporting

confidence: 82%

“…However, our study still provides a representative sample of breast cancer patients treated in oncology centers today. Comparable studies, analyzing, e.g., the information-seeking behavior of breast cancer patients, achieve comparable patient numbers and come to comparable results ( 31 ). Therefore, we were able to present qualitative data on the important wishes and needs of these patients and can also provide important subgroup analyses.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

What are the needs in oral antitumor therapy? An analysis of patients’ and practitioners’ preferences

Hester,

Henze,

Debes

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundSince the European approval of CDK4/6 inhibitors in 2016, the treatment of patients with hormone-receptor-positive, HER2-negative metastatic breast cancer has changed significantly. Compared with chemotherapy, endocrine-based therapy has different treatment regimens and is associated with new side effects. Oral therapy aims for optimal drug efficacy and long treatment times while maintaining maximum independence and quality of life resulting in the conservation of medical staff resources.MethodsA monocentric analysis of therapy preferences of practitioners (25 nurses and physicians) and patients (11 on endocrine monotherapy, 17 on endocrine-based therapy, and 14 on intravenous chemotherapy) was performed using specific questionnaires. Preferences were assessed using a four-point Likert scale or bidirectional response options.ResultsAll patients were highly supportive of oral therapy (mean agreement score on the Likert scale 1.3, p < 0.001 vs. all other options) and a consultation interval of 4 weeks (2.0, p = 0.015 vs. 3 weeks). Practitioners also preferred oral therapy (1.4) and visits every 4 weeks (1.6). In general, patients on oral therapies reported higher compatibility of their therapy with daily life than patients on chemotherapy (1.6 and 1.7 vs. 2.6, p = 0.006). Outpatient oncology is the main source of information for all patients, mainly in case of side effects (2.0) and open questions (1.8). Regarding oral antitumor therapy regimens, patients do not show a significant preference for a specific regimen, while practitioners prefer a continuous regimen (1.6) over a 21/7 regimen (21 days on and 7 days off therapy, 2.5). Patients are likely to accept mild side effects (e.g., neutropenia, diarrhea, polyneuropathy, fatigue) and would still adhere to their initial choice of regimen (continuous or 21/7). Only when side effects occur with a severity of CTCAE grade 3 do patients prefer the regimen in which the side effects occur for a shorter period of time.ConclusionPatients and practitioners prefer oral antitumor therapy—both continuous and 21/7 regimens—over other application forms. Patient education and proper therapy management, supported by additional tools, contribute to the specific management of side effects and high adherence. This allows quality of life to be maintained during long-term therapy with CDK4/6 inhibitors in patients with metastatic breast cancer.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%